Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.40 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.40 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.40 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15352178 | 0.98 | CA2 (0.53) | CA2TAAR1HTR2ACYP4A11CYP4F2 | |
| SCHEMBL16414630 | 0.98 | CA2 (0.53) | CA2TAAR1HTR2ACYP4A11CYP4F2 | |
| SCHEMBL5310822 | 0.98 | CA2 (0.53) | CA2TAAR1HTR2ACYP4A11CYP4F2 | |
| SCHEMBL1046537 | 0.98 | CA2 (0.53) | CA2TAAR1HTR2ACYP4A11CYP4F2 | |
| SCHEMBL2382177 | 0.98 | CA2 (0.53) | CA2TAAR1HTR2ACYP4A11CYP4F2 | |
| SCHEMBL16414852 | 0.98 | CA2 (0.53) | CA2TAAR1HTR2ACYP4A11CYP4F2 | |
| SCHEMBL16467630 | 0.98 | CA2 (0.53) | CA2TAAR1HTR2ACYP4A11CYP4F2 | |
| SCHEMBL1044964 | 0.98 | CA2 (0.53) | CA2TAAR1HTR2ACYP4A11CYP4F2 | |
| SCHEMBL5515 | 0.93 | TAAR1 (0.52) | CA2TAAR1HTR2ACYP4A11CYP4F2 | |
| SCHEMBL242504 | 0.87 | CA2 (0.61) | CA2CYP4A11CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235840-A1 | ECHINOCANDIN-LIKE AND BORON-CONTAINING ECHINOCANDIN COMPOUNDS AND THEIR USE AS AGROCHEMICAL FUNGICIDES | 5METIS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12398168-B2 | Preparation method of a glycoside compound | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2025-08-26 | — | — | US | disclosed |
| EP-4140974-B1 | METHODS OF IRON CATALYZED C-H BOND AMINATION | VERSITECH LTD (CN) | 2025-05-14 | — | — | EP | disclosed |
| US-12286426-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2025-04-29 | — | — | US | disclosed |
| CN-118955244-A | Method for preparing primary alcohol by homogeneously catalyzing and reducing carboxylic acid derivative by using N-heterocyclic carbene copper complex | 延安大学 | 2024-11-15 | — | — | CN | disclosed |
| EP-3704111-B1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2024-10-09 | — | — | EP | disclosed |
| US-12098126-B2 | Methods of iron catalyzed C-H bond amination | VERSITECH LIMITED (CN) | 2024-09-24 | — | — | US | disclosed |
| CN-112209908-B | Glucopyranosyl derivatives and uses thereof | 东莞市东阳光新药研发有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-111886234-B | Heterocyclic mitochondrial activity inhibitors and uses thereof | 蒙特利尔大学 | 2023-12-15 | — | — | CN | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
| WO-2002032422-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| EP-1107944-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012462-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-09 | — | — | WO | disclosed |
| CN-1040321-C | Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses | UPJOHN CO (US) | 1998-10-21 | — | — | CN | disclosed |
| EP-0668860-A1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | PHARMACIA & UPJOHN COMPANY (US) | 1995-08-30 | — | — | EP | disclosed |
| EP-0247381-B1 | 5-FLUROROURACIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-5047521-A | Anticarcinogenic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, IDH1 | CA2 425/4885TAAR1 4509/4885HTR2A 4698/4885 |
| US-12098126-B2 | Methods of iron catalyzed C-H bond amination | FTH1, FECH, HCCS | CA2 1088/4885TAAR1 1185/4885HTR2A 1233/4885 |
| US-12398168-B2 | Preparation method of a glycoside compound | GALE, ST6GAL1, MGAM | CA2 1160/4885TAAR1 4827/4885HTR2A 3877/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | CA2 3323/4885TAAR1 493/4885HTR2A 853/4885 |
| US-12286426-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, IDH1 | CA2 425/4885TAAR1 4509/4885HTR2A 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.